Urogen Pharma ((URGN)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: UroGen Pharma is conducting a Phase 3, single-arm, multicenter study to evaluate the efficacy and safety of UGN-104, a novel formulation of UGN-101, for treating patients with low-grade upper tract urothelial cancer (LG-UTUC). This study aims to provide a new therapeutic option for LG-UTUC, a condition with limited treatment alternatives, enhancing patient outcomes and expanding UroGen’s product portfolio.
Intervention/Treatment: The study tests UGN-104, an experimental drug consisting of mitomycin and a proprietary thermally responsive hydrogel. This formulation allows for local administration in the upper urinary tract, where it converts into a semi-solid gel, delivering mitomycin directly to the cancer site.
Study Design: This interventional study follows a single-group model with no masking, focusing primarily on treatment. Participants receive UGN-104 weekly for six weeks, with potential monthly maintenance doses for responders, aiming to assess the drug’s therapeutic efficacy and safety.
Study Timeline: The study began on January 8, 2025, with the latest update submitted on July 17, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence market dynamics.
Market Implications: UroGen Pharma’s ongoing study of UGN-104 could significantly impact its stock performance, as successful results may lead to expanded market opportunities and increased investor confidence. This development positions UroGen competitively within the urothelial cancer treatment landscape, potentially affecting industry dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.